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LC–MS/MSHuman immunodeﬁciency virus type 1 (HIV-1) infects both activated CD4+T cells andmacrophages.We tested
if liquid chromatography–tandemmass spectrometry (LC–MS/MS) technology canmonitormetabolic alterations
induced by HIV-1 in the infected cells. Here we monitored glucose uptake and conducted LC–MS/MS-based
metabolomic analysis in HIV-1 infected primary human CD4+ T cells and a macrophage model system:
differentiated U1 (HIV-1 producing) and differentiated U937 (control) cells. HIV-1 infected CD4+ T cells have
higher glucose uptake and increases in severalmetabolite pool sizes, whereas HIV-1 producingmacrophages had
substantial reductions in glucose uptake and steady state glycolytic intermediates. This data suggests that the two
HIV-1 target cell typesexhibit verydifferentmetabolic outcomesduringviral production. This study also validates
the LC–MS/MS technology as an effective metabolomic approach tomonitor various metabolic alterations made
by HIV-1 infection.y and Immunology, University
72, Rochester, NY 14642, USA.
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Cellular metabolic pathways, such as glycolysis, tricarboxylic acid
cycle (TCA cycle), lipid metabolism, amino acid and nucleotide
synthesis, are targeted during viral infections to support the production
of 1000 to 20,000 new viral progeny per infected cell (Chen et al., 2007;
Horsfall, 1954). Recently studies show that human cytomegalovirus
(HCMV) alters numerous aspects of host-cell metabolism, some of
which were found to be critical for viral replication (Chambers et al.,
2010; McArdle et al., 2011; Munger et al., 2008). Hepatitis virus type C
infection has been shown to induce dysregulation of glucose utilization
and lipid biosynthesis (Blackham et al., 2010; Herker et al., 2010;
Mankouri et al., 2010). Many viruses, including poliovirus, Dengue,
Epstein Barr virus and Human Immunodeﬁciency Virus type 1 (HIV-1),
usurp the autophagy pathways, which are involved in sensing nutrient
deprivation and energy stress, for the beneﬁt of viral infection, immune
evasion, and viral replication (Heaton and Randall, 2010; Shoji-Kawata
and Levine, 2009).
HIV-1 causes acquired immune deﬁciency syndrome, and it
uniquely infects both activated CD4+ T cells and terminally
differentiated macrophages during the course of HIV-1 pathogenesis.
While HIV-1 infection of CD4+ T cells induces G2 arrest and cell death
within 2–3 days (Jowett et al., 1995), HIV-1 infection of macrophages
leads to long-lived survival and low constitutive viral production,generating viral reservoirs (Cosenza et al., 2004; Kilareski et al., 2009),
which contribute to HIV-1 associated neurodegenerative diseases in
the CNS (Cysique and Brew, 2009).
Collectively, it is becoming increasingly apparent that upon viral
infection changes occur in the metabolic proﬁle of the cell, which are
critically important for viral replication. With this in mind, we sought
to determine how HIV-1 impacts the cellular metabolic environments
in activated CD4+ T cells and macrophages. Recent advances in
metabolomic methodologies, such as LC–MS/MS technology, enable
the simultaneous measurement of numerous cellular metabolic
intermediates allowing for the elucidation of highly complex
metabolic outcomes induced by viral infections at steady state level
(Munger et al., 2006, 2008). Our previous HCMV ﬁndings indicate
increased glucose uptake in HCMV-infected ﬁbroblasts as compared
to mock-infected cells. These data were further supported by
increased steady state glycolytic and TCA-cycle metabolite pool
sizes within the cells coupled with faster metabolite ﬂux through
glycolysis and TCA intermediates upon HCMV infection (Munger et al.,
2008).
Due to the long-lived nature of HIV-producing macrophages, we
hypothesized that the cellular metabolic landscape of HIV-infected
macrophages could be different from that of HIV-infected CD4+ T cells,
which were previously reported to robustly upregulate some cellular
metabolic events (Chan et al., 2009). In addition, no metabolomic
analysis on long-living, persistently infected cells has yet been reported.
Therefore, in this study, we tested our hypothesis by monitoring the
metabolic alterations that occur during viral production from primary
CD4+ T cells and an HIV-1 infected humanmacrophage model system.
Indeed, we ﬁnd that the two HIV-1 target cell types have very different
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increased uptake of tritiated glucose, whereas infected macrophages
have signiﬁcantly reduced uptake of tritiated glucose. Using LC–MS/MS-
basedmetabolomic analysis, we ﬁnd that several steady state glycolytic
intermediates are signiﬁcantly upregulated in CD4+ T cells, whereas
macrophages have signiﬁcantly reduced level of several metabolites.
Moreover, we ﬁnd signiﬁcant changes in severalmetabolites in the PPP,
TCA cycle, and UDP-sugars for both cell types. We also examined NTP
pools and found signiﬁcant changes only for macrophages. Lastly, we
examined ATP/ADP, NAD+/NADH and NADP+/NADPH ratios and
found only macrophages have a signiﬁcant change in the NADP+/
NADPH ratio. Our LC–MS/MS data help provide a clearer understanding
of cell type speciﬁc metabolic changes associated with HIV-1 viral
replication.
Results and discussion
In this study, our goal is to test if the LC–MS/MS technology can
monitor HIV-1 induced cellular metabolic alterations in CD4+ T cells
andmacrophages. To test this we compared HIV-1 infected versus non-
infected primary human CD4+ T cells from the same donor (Fig. 1a).
CD4+ T cells were infected with NLEGN-1 HIV-1 virus, which is the
infectious HIV-1 NL4-3 stain that has all viral genes expressed in
addition to GFP (Kutsch et al., 2002). CD4+ T cells were FACS-sorted
into GFP+ (HIV-1 producing) and GFP− cells from the same donor,
achieving 7–20% infection at the time of sorting. All CD4+ T cell
experiments compared infected versus uninfected T cells at the same
time for individual donors.
Due to the nature of macrophages being difﬁcult to infect
completely with HIV-1 and their tendency not to re-adhere once
detached, we utilized a cell linemodel tomimic humanHIV-1 infected
macrophages (Fig. 1b). The human promonocytic U937 cells are the
most commonly used HIV-1 monocyte/macrophage model system
(Cassol et al., 2006). U1 cells are chronically HIV-1 infected U937 cells
(Folks et al., 1987) and are widely used as a model system to study
HIV-1 biology inmacrophages (Bristow et al., 2008; Cassol et al., 2006;
Fernandez Larrosa et al., 2008; Olivares et al., 2009; Spector and Zhou,
2008). U937 and U1 cells were differentiated into macrophages using
Vitamin D3 and PMA treatment (Fig. 1b). U1 cells produced virus
within 2 days as measured by intracellular expression and secreted
p24 (Supplemental data 2a and b). In addition, U1 cells remained alive
and have comparable cell death to U937 cells (Supplemental data 2c
and d), indicating that HIV-1 production does not induce apoptosis for
U1 cells, which is similar to what we observe with primary human
macrophages.Fig. 1. Diagram of methods. a) Primary CD4+ T cells were expanded in culture in the
presence of 5 μg/ml PHA and 10 ng/ml IL-2. After 5 days the cells were infected with
NLEGN-1 HIV-1 virus for 24 h before FACS sorting the cells into GFP+ (HIV-1 producing
cells) and GFP− (control) populations. The cells were allowed to recover for 6 h in
DMEM media containing 10% FBS before being used for LC–MS/MS or glucose uptake
assays. b) U1 and U937 cells were maturated in the presence of 10 nM Vitamin D3 for
two day prior to 100 nM PHA treatment for 1 h. Cells were then washed three times
with media, counted and plated at 2 million cells/well. At day 2 of differentiation,
macrophages were used for experiments.A basic overview of metabolic pathways is illustrated in Fig. 2a
showing the many different pathways that glucose can travel once
entering the cell (Wamelink et al., 2008). First, we used tritiated 2-
deoxyglucose (2-DOG) to monitor the cellular capacity for glucose
uptake (Reusch et al., 1991). As shown in Fig. 2b and Supplemental
data 3a, HIV-1 infected CD4+ T cells (GFP+) from three different
human donors have a signiﬁcant increase in 2-DOG uptake as
compared to GFP− CD4+ T cells (control) from the same donor
under the same culture conditions. In contrast, when we examined
glucose uptake of the U937 and U1 macrophage model system, and
observed that U1 macrophages have a signiﬁcant reduction in 2-DOG
uptake as compared to U937 macrophages (Fig. 1b and Supplemental
data 3b). Since U1 and U937 cells have been passaged for many years,
there may be additional, subtle changes that have occurred to both
cell lines. However, both U1 and U937 cells have comparable 2-DOG
uptake before differentiation (Supplemental data 3c), suggesting no
predisposed gross changes in glucose uptake in latently infected U1
cells is observed. Overall, the absence of glucose uptake enhancement
in U1 macrophages (HIV-1 producing) versus U937 macrophages
implies that HIV-1 production does not induce additional glucose
uptake during virus production. This ﬁnding is in contrast to our HIV-1
infected CD4+ T cell data (Fig. 2b) and the observations of another
lytic viral infection (Munger et al., 2006, 2008).
Nextwe used LC–MS/MS to examine steady state levels ofmetabolic
intermediates during viral infection. For HIV-1 infected CD4+ T cells
and macrophage model system, a total of 66metabolic small molecules
were identiﬁed during steady state analysis (Supplemental Table 1:
complete list). Our data for HIV-1 infected CD4+ T cells (analyzed as
ratio of GFP+/GFP) indicate that several glycolytic key metabolites:
hexose-P, fructose 1,6-bisphosphate (FBP), glyceraldehyde-3P (G3P)
and 3-phosphoglycerate (3PG) have signiﬁcantly increased pool sizes
by T-test analysis (Fig. 3a; shown as Log2 converted data). This data
together with the increased glucose uptake (Fig. 2b), suggests an
increased rate of glycolysis for HIV-infected CD4+ T cells. These
observations parallel previous ﬁndings in which increases in glycolytic
metabolite concentrations correlated with increased glycolytic ﬂux
(Munger et al., 2006, 2008).
Next, we examined metabolic pools in macrophage model system
(analyzed as the ratio of U1/U937) and found signiﬁcant reductions in
glycolytic intermediates: hexose-P, FBP and G3P (Fig. 3a). Coupled
with the decrease in glucose uptake (Fig. 2b), these results suggest an
HIV-induced suppression of glycolysis inmacrophages. One surprising
aspect of these data is the increase in pyruvate pool size despite the
reduction of glucose uptake and decreased FBP levels. This could
reﬂect either decreased pyruvate consumption by the TCA cycle in
macrophages or perhaps increased pyruvate production from other
carbon sources such as amino acid oxidation. Regardless, these data
indicate that HIV-1 infection in CD4+ T cells and macrophages has
very different metabolic outcomes.
Next, we examined metabolite pool sizes for the TCA cycle. As
shown in Fig. 3b, aconitate and isocitrate are signiﬁcantly increased
for HIV-1 infected CD4+ T cells, while HIV-1 producing macrophages
have a signiﬁcantly larger malate pool. Collectively, the lack of
detectable changes in multiple metabolite pool sizes suggests that the
viral impact on the TCA cycle is not analogous to its impact on
glycolysis. Ringrose et al. reported that several TCA cycle proteins are
upregulated during late HIV-1 infection (Ringrose et al., 2008). While
we do detect substantial changes to a few TCA metabolite pool sizes,
we cannot clearly delineate this impact on the TCA cycle. Moreover,
our data does not address HIV-modulation of TCA cycle ﬂux or
changes in metabolite pool sizes that feed into and out of the TCA
cycle for other biosynthesis pathways. These data are in contrast to
earlier ﬁndings for HCMV infection which showed increases in TCA
cycle intermediates (Munger et al., 2006, 2008), suggesting that
evolutionarily divergent viruses interact differently with the host-cell
metabolic network. Alternatively, activation of glycolysis is sufﬁcient
Fig. 2. Diagram of metabolic pathways. FBP is the major regulatory metabolite for glycolysis. It inﬂuences its own production and pyruvate, to stimulation of more glucose
consumption. Pyruvate can be converted into lactate or further be processed to enter the TCA cycle. Alternative pathways of glucose use are the PPP, glycogen synthesis and
glycosylation of proteins. The oxidative PPP is unidirectional and generates NADPH, whereas the non-oxidative PPP is reversible, allowing excess ribose to be converted into
glycolytic intermediates or ribose generation from intermediates. b) Glucose uptake assay was performed as described in Methods. Glucose uptake is shown for CD4+ T cells as the
ratio of GFP+/GFP− (HIV-1+ positive/HIV-1 negative cells) and the ratio of U1/U937 macrophages (HIV-1 producing/control cells). Three independent experiments were done in
triplicate for each cell type. Data displayed as Log2 converted and SEM.
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larger DNA genome (230 kb) as compared to the small RNA genome
(9.5 knt) of HIV-1, may require greater metabolic resources thus
promoting the activation of both glycolysis and the TCA cycle.
Next we examined metabolite pool sizes. For the PPP, HIV-1
infected CD4+ T cells have a signiﬁcant increase in sedoheptulose 7-P
(S7P; non-oxidative PPP) and ribose-P, whereas macrophages have a
signiﬁcant decrease in 6-P-gluconate (6PG; oxidative PPP) and no
signiﬁcant change in S7P and ribose-P (Fig. 4a). These data suggest
that infected CD4+ T cells may use the non-oxidative PPP to generate
ribose at this late time point after infection. In addition, the PPP
metabolite 6PG level is not signiﬁcantly different (Log2=−0.09).
These data are consistent with Chan et al.; they showed no difference
at the enzyme level for this metabolite at a late time point of infection
(Chan et al., 2009). HIV-1 has an RNA genome; therefore we also
examined nucleotide triphosphate (NTP) pool sizes in CD4+ T cells
and macrophages. We recently reported that macrophages have a
slightly lower NTP pools than activated PBMC, and the concentrations
of pyrimidines are lower than purines (Kennedy et al., 2010). As
shown in Fig. 4b, no signiﬁcant differences in NTP pool sizes were
detected for CD4+ T cells. Yet for the macrophage model system, the
pyrimidines: CTP and UTP pool sizes were signiﬁcantly increased. We
detected a decrease in GTP, yet this did not reach the level of
signiﬁcant difference using paired T-test.Wenext examined the ATP/ADP, NAD+/NADHandNADP+/NADPH
ratios (Fig. 4c and Supplemental data 4). For both cell populations, the
ATP/ADPandNAD+/NADH ratioswere not signiﬁcantly different. These
data supported our conclusion of very little change in the TCA cycle by
HIV-1 infection. It has been well established for HIV-1 and other viruses
that the redox levels: glutathione and NADPH, change within the
infected cells (Gu et al., 2001; Jana and Pahan, 2004; Korenaga et al.,
2005; Sagi and Fluhr, 2001). The NADP+/NADPH ratio formacrophages
was signiﬁcantly different, but not for CD4+ T cells (Fig. 4c). This data
and the 6PG PPP metabolite data suggest an overall reduction in the
ability to generate NADPH. Furthermore, these data suggest that HIV-1
producing U1 macrophages may be compromised in their ability to
generate de novo nucleotides and fatty acids. This can be addressed in
future studies using more tradition biochemical assays.
Finally, we examined the UDP-sugar pools within the different cell
types. UDP-sugars are metabolic intermediates used in glycosylation
of proteins. HIV-1 gp120 and gp41proteins are highly glycosylated,
are key targets for antibody binding to prevent infection, and are
critical for HIV-1 pathogenesis (Monteﬁori et al., 1988; Pal et al., 1989;
Raska et al., 2010). We detect a signiﬁcant increase in UDP-glucose
pool size for CD4+ T cells (Fig. 4d). UDP-D-glucurononate pool size
was not signiﬁcantly changed in either CD4+ T cells or macrophages.
UDP-N-acetyl-glucosamine pool size was signiﬁcantly increased in
both CD4+ T cells and macrophages, whereas N-acetyl-glucosamine-
Fig. 3. LC–MS/MS analysis of glycolysis and TCA cycle metabolic pools. a) LC–MS/MS
analysis of glycolytic intermediates for CD4+ T cells (solid) and macrophages (open)
are shown as fold change in data. Metabolites that have a signiﬁcant difference are
denoted with asterisks. b) TCA cycle intermediate pool sizes are compared as described
above. For CD4+ T cells, the ratio of GFP+/GFP−metabolite intensities was compared,
whereas the ratio of U1/U937 metabolite intensities is shown for macrophages.
Signiﬁcant differences were determined using paired T-test. For CD4+ T cells, four
independent donors were done in duplicate (n=8). Seven LC–MS/MS runs were
compared for U1 and U937 cells. Data displayed as Log2 converted and SEM.
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data indicate that UDP-sugar pathways may be potential targets for
metabolic chemical inhibitors, since they are increased in both cell
types. Future experiments will need to be done in order to conﬁrm
that reducing UDP-sugar synthesis has an effect on HIV-1 viral
replication.
Clearly our data indicates that LC–MS/MS technology is attractive
when measurement of multiple metabolic intermediates is desired.
Our strongest data using LC–MS/MS comes from the analysis of
glycolytic intermediates (Fig. 3a), which will require additional future
studies to examine both RNA and protein levels under these
conditions. The limitations of these results are 1) the relative low
detection sensitivity presumably due to the limited biomass sizes,
compared to the previous HCMV data, particularly in PPP and TCA
pathways (Munger et al., 2006, 2008), 2) the potential delay of sample
preparation for suspension cells, which requires centrifugation before
lysis, which may be problematic for metabolic kinetic readouts (i.e.
ﬂux analysis), as compared to adherent cells which can be directly
methanol lysed on the plates, and ﬁnally, 3) the difﬁcult nature of
primary human macrophage infection from donor to donor. Thesetechnical limitations partially attribute cell types used during this
study, and require further work.
Conclusion
Our data suggests that the two HIV-1 target cell types exhibit very
different metabolic outcomes during viral production, and this study
also validates the LC–MS/MS technology as an effective metabolomic
approach to monitor various metabolic alterations made by HIV-1
infection.
Materials and methods
Cells
The U937 cell line was purchased from the American Type Culture
Collection, whereas the U1 cell line was acquired through the NIH
AIDS Research and Reference Program. Both cell lines were grown in
RPMI 1640 media supplemented with 10% FBS and penicillin and
streptomycin antibiotics (complete media). Cells were split 1:5
dilution and treated with 10 nM Vitamin D3 (Sigma) at day −2. At
day −1, media was doubled and supplemented with Vitamin D3. At
day 0, cells were transferred to 50 ml tubes and treated with 100 nM
PMA for 2 h. Cells were washed three times with PBS, resuspended in
10 ml of completemedia and counted. Twomillion cells per well were
plated in 6-well plate with a ﬁnal volume of 4 ml/well of RPMI 1640
media with 10% FBS. After 2 days of differentiation, U937 and U1 cells
were used for experiments.
Primary human CD4+ T cells were positively selected for using
MACS isolation from buffy coats (New York Blood Services, Long Island,
NY). Cells were at 10 million cells/ml stored at−80 °C before use. For
CD4+T cells activation, 60–120 million cellswere thawed andplaced in
media. Cells were centrifuged at 1200 rpm for 7 min. The pellet was
resuspended in 15 ml of DMEM media containing 5% FBS/30 million
cells. The cell suspension was placed in a T75 ﬂask and 5 ug/ml of PHA
(Sigma) and 10 ng/ml IL-2 (Roche; NIH AIDS Research and Reference
Reagents) were added. At day 2, 7.5 ml DMEMmedia and 10 ng/ml IL-2
were added. At day 3, cells were centrifuged at 1200×g rpm for 7 min.
Two T75 ﬂasks were combined and pellets resuspended in 40 ml of
DMEMmedia with 10 ng/ml IL-2. Cells were allowed to expand for two
more days. At day 5, cells were harvested at 1200 rpm for 7 min. Cells
were resuspended in 10 ml of media and counted.
HIV-1 virus generation
pNLEGN-1 was a kind gift from Dr. Levy (Kutsch et al., 2002).
Plasmid was transfected into Stable 2 Escherichia coli strain and then
Qaigen Maxi preparation was done. 292FT cells (Invitrogen) grown in
T225 ﬂasks were transfected with 60 μg pNLEGN-1 and 10 μg pVSV-g
plasmids using 140 μl polyethyenimine (1 mg/ml) in 37 ml DMEM
media/ﬂask. Day 1 HIV-1 production was discarded and fresh DMEM
media+0.1% DMSO were added. At day 2, media was harvested and
replaced with fresh DMEM media+0.1% DMSO. The media was
centrifuged at 3500 rpm for 7 min to remove cellular debris. Media
was stored at 4 °C in T75 ﬂask. Day 2 media was harvested and
processed as day 1. Both days of collection were pooled and FBS was
added to 5% volume. In addition, 10 ng/ml IL-2 was added to the T75
ﬂask. This large cocktail was then used to infect the primary activated
CD4+ T cells.
CD4+ T cell infection
Ten million activated CD4+ T cells were placed in 15 ml of HIV-1
media (TPP petri dishes). Dishes were placed on an orbital shaker for
24 h in the incubator. We found that this led to the fastest increase in
GFP+ cells. Cells were then harvested from the dishes and centrifuged.
Fig. 4. LC–MS/MS analysis of metabolites used in viral production. a) PPP pathway was examined for CD4+ T cells (solid) and macrophages (open). Signiﬁcantly different
metabolites are indicated by asterisks. b) NTP pools were examined and found to change more for macrophages than T cells. c) The APT/ADP, NAD+/NADPH and NADP+/NADPH
ratios were examined for the different cell types. d) Sugar derivative pool sizes were examined using LC–MS/MS analysis. Data sets are stated and plotted as indicated in Fig. 3 legend.
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tubes.Additionalmediawas added toadjust cells/ml to under50 million
before sorting.
FACS sorting
The University of Rochester has a FACS Core Facility. Cells were
FACS Sorted using BD FACS Aria IIu machine, which is in a BioProtect
III hood (The Baker Co.) using BSL-2+ conditions. Single T cells were
discriminated using FSC and SSC parameters before sorting GFP+
(HIV-1+) and GFP− (HIV-1 negative) populations. The gating proﬁle
from the FACS sorter is shown in Supplemental data 1 and shown a
very tight gate GFP− cells and a liberal collection gate for GFP+ cells.
We had between 7 and 20% GFP+ populations for the seven different
donors. This determined as to which type of experiment was done
after sorting. We needed 3 million cells/tube for LC–MS/MS, whereas
the glucose uptake assay had 1.5–2 million cells/tube. CD4+ T cells
were analyzed in duplicate for LC–MS/MS analysis, whereas triplicate
samples for each of the GFP+ and GFP− populations were analyzed
for the glucose uptake assay.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
For U1 and U937 cells steady state analysis, media was removed
from day 2 differentiated cells and replaced with serum-free DMEMmedia lacking sodium pyruvate. After 1 h at 37 °C, the media was
aspirated and dry ice cold 80% methanol was added. Samples were
stored at −80 °C for 5 min followed by processing with a rubber
policeman to remove attached cells. Supernatant was transferred to a
15 ml conical tube and vortexed for 1 min. Samples were centrifuged
at 3500 rpm for 5 min. The supernatant was transferred to a new tube.
Pellets were washed with 1 ml of dry ice cold 80% methanol. Samples
were centrifuged and supernatants consolidated for each sample.
Samples were dried under nitrogen gas. Once dried, samples were
stored at −80 °C until analysis.
For FACS Sorted CD4+ T cells, 3×106 cells were placed in cryovials
with DMEM containing 10% dialyzed FBS serum. Cells were allowed to
recover for 6 h in the tissue culture incubator. After recovery time, each
sample was centrifuged at 4 K rpm for 10 s. Supernatant was removed
using vacuum and 1 ml of dry ice cold 80% methanol was added. Tubes
were vortexed for 1 min, and then centrifuged at 15 K rpm for 1 min.
Supernatant was removed and placed in a 15 ml tube. Cell pellet was
washed with 0.5 ml dry ice cold 80% methanol. Tubes were centrifuged
again and supernatants pooled. Supernatants were dried using nitrogen
gas. Once dried, samples were stored at−80 °C until analysis.
Samples were removed from the −80 °C and allowed to
equilibrate to room temperature. The cell pellet was resuspended in
100 μl 50% methanol and liquid transferred to 1.5 ml centrifuge tube.
Cellular debris was removed by 15 K rpm centrifugation for 10 min
and 75 μl of supernatant was transferred to a LC–MS/MS vial and
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system (Shimadzu) formetabolite separation. The LC was coupled to a
mass spectrometer running in negativemodewith an ESI source using
reversed phase chromatography with an amine-based ion pairing
agent. A Synergi Hydro-RP column (150 by 2 mmwith a 5-μmparticle
size; Phenomenex) was used with the following LC parameters:
autosampler temperature, 4 °C; column temperature, 40 °C; ﬂow rate,
and 200 μl/min. The LC solvents were as follows: solvent A, 100%
methanol; solvent B, 10 mM tributylamine and 15 mM acetic acid in
97:3 water–methanol. The HPLC gradients were as follows: for t=0,
100% B; for t=5, 100% B; for t=10, 80% B; for t=20, 80% B; for t=35,
35% B; for t=38, 5% B; for t=42, 5% B; for t=43, 100% B; and for
t=50, 100% B. Mass spectrometric analyses were performed with a
TSQ Quantum Ultra triple–quadrupole mass spectrometer (Thermo
Fisher Scientiﬁc) with mass spectrometry parameters as per Bajad
et al.(2006).
Data analysis and graphing
MS data were acquired using Xcalibur software (Thermo Fisher
Scientiﬁc). Each metabolite measurement was in the form of a
selected reaction monitoring scan event (SRM) occurring at a speciﬁc
HPLC retention time. Each SRM consists of: a metabolite speciﬁc
parent ion m/z, a collision cell energy, and a metabolite-speciﬁc
product ion resulting from collisionwith argon gas in the collision cell.
Metabolite retention times and SRMS were previously empirically
determined using pure chemical standards and have formerly been
reported (Bajad et al., 2006). The resulting data were exported into
mzRock free shareware (http://code.google.com/p/mzrock/), which
allows automated analysis of targeted metabolomics data. To quantify
metabolite levels, peak heights for different metabolite SRMs were
determined for each sample. A metabolite was not analyzed further if:
(i) its signal for all viral and mock samples was undetectable; (ii) its
maximum signal for all viral ormock samples was less than 2-fold that
of the maximum signal in the methanol control sample; or (iii) the
observed signal likely resulted from a naturally occurring heavy
isotope of another metabolite. Data from each donor set was
compared pair wise as they were run and paired T-test used to
evaluate signiﬁcant differences. Data was plotted with standard error
of mean (SEM) using Prism software (GraphPad Software).
2-DOG uptake assay
For U1 or U937 cells, 1×106 cells/well were differentiated in 12-well
plates. At day 2 of differentiation, media was removed and cells cultured
for2 hunder serumfree conditions. After incubation,mediawas replaced
with 0.5 ml DMEM media (glucose free) containing 1.0 μCi 2-DOG/ml.
Cells were cultured for 10 min at 37 °C. Preliminary assays were done
withmacrophage and 293FT cells and found that 2-DOG uptakewas still
in the linear range even after 30 min of incubation (data not shown).
Afterwards, the plates were placed on ice, media removed, cells washed
thrice with ice cold PBS. Cells were lysed using ELB buffer with 0.1% SDS
for 20 min at 37 °C. Scintillation counts were collected using 0.4 ml. Data
was normalized to total protein (BioRad protein assay). Samples were
done in triplicate.
For CD4+ T cells, 1.5–2×106 cells were placed in cryovials with
complete DMEM media after FACS sorting. The cells were allowed to
recover for 6 h. The vials were then closed and centrifuged at 4 K rpm
for 10 s. The media was removed by aspiration, and 0.5 ml DMEM
media (glucose free) containing 1.0 μCi 2-DOG/ml was added. The
cells were incubated at 37 °C for 10 min, before being centrifuged at
4 K rpm for 15 s. Media was carefully removed and cell pellet washed
once with ice cold PBS. After centrifugation, the pellet was lysed using
ELB buffer with 0.1% SDS for 20 min at 37 °C. Scintillation counts were
collected using 0.4 ml. Data was normalized to total protein. Samples
were done in triplicate for three independent donors.Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.04.007.
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